Jun 13, 2026 07:30AM
Jun 13, 2026 07:30AM
Jun 1, 2026 07:30AM
Jun 1, 2026 07:30AM
May 11, 2026 07:30AM
Apr 27, 2026 02:50PM
Apr 27, 2026 10:10AM Intellia Therapeutics (NTLA) PT Raised to $20 at BofA Securities
Apr 27, 2026 07:03AM
Apr 27, 2026 07:00AM
Apr 27, 2026 07:00AM
Apr 27, 2026 07:00AM
Apr 8, 2026 09:15AM
Mar 4, 2026 06:01AM
Mar 3, 2026 09:54AM Brookline Capital Markets Reiterates Buy Rating on Intellia Therapeutics (NTLA), PT $106
Mar 3, 2026 07:30AM
Mar 3, 2026 07:30AM
Mar 3, 2026 04:56AM
Mar 2, 2026 03:25PM
Mar 2, 2026 02:48PM
Mar 2, 2026 02:18PM
Mar 2, 2026 02:04PM Oppenheimer on Intellia Therapeutics (NTLA): 'We view the resolution of the clinical trial holds for nex-z as relatively fast and favorable'
Mar 2, 2026 12:28PM
Mar 2, 2026 12:05PM
Mar 2, 2026 10:25AM
Mar 2, 2026 07:30AM
Mar 2, 2026 07:30AM
Feb 26, 2026 01:28PM
Feb 26, 2026 07:30AM Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Jan 27, 2026 11:29AM
Jan 27, 2026 08:00AM
Jan 27, 2026 08:00AM
Dec 19, 2025 09:06AM
Nov 18, 2025 08:45AM
Nov 10, 2025 03:17PM
Nov 10, 2025 03:17PM Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
Nov 8, 2025 05:13PM
Nov 8, 2025 05:13PM
Nov 7, 2025 08:56AM
Nov 6, 2025 04:00PM
Oct 31, 2025 09:54AM
Oct 31, 2025 07:27AM
Oct 30, 2025 04:55AM Intellia Therapeutics (NTLA) PT Lowered to $9 at Baird
Oct 29, 2025 04:24PM
Oct 28, 2025 06:26AM
Oct 27, 2025 07:31AM
Oct 27, 2025 07:30AM
Sep 18, 2025 07:30AM
Sep 18, 2025 07:30AM
Aug 30, 2025 04:00PM Why public perception matters so much for biotech valuations
Jun 15, 2025 10:45AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All